Aytu BioPharma, Inc. (AYTU) DCF Valuation

Aytu BioPharma, Inc. (AYTU) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Aytu BioPharma, Inc. (AYTU) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore Aytu BioPharma, Inc. (AYTU) financial potential with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate Aytu BioPharma, Inc. (AYTU) intrinsic value and inform your investment decisions.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue 27.6 65.6 96.7 107.4 81.0 108.1 144.3 192.5 256.9 342.9
Revenue Growth, % 0 137.52 47.29 11.1 -24.58 33.45 33.45 33.45 33.45 33.45
EBITDA -12.2 -29.0 -28.0 -3.5 -1.0 -26.3 -35.2 -46.9 -62.6 -83.6
EBITDA, % -44.18 -44.25 -28.92 -3.27 -1.25 -24.37 -24.37 -24.37 -24.37 -24.37
Depreciation 4.6 7.7 10.1 8.8 8.3 12.4 16.5 22.0 29.4 39.3
Depreciation, % 16.61 11.73 10.5 8.21 10.21 11.45 11.45 11.45 11.45 11.45
EBIT -16.8 -36.7 -38.1 -12.3 -9.3 -38.7 -51.7 -69.0 -92.0 -122.8
EBIT, % -60.79 -55.98 -39.42 -11.48 -11.46 -35.82 -35.82 -35.82 -35.82 -35.82
Total Cash 48.1 49.6 19.4 23.0 20.0 52.3 69.8 93.1 124.2 165.8
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 5.6 28.2 21.7 28.9 23.6
Account Receivables, % 20.39 42.93 22.46 26.94 29.16
Inventories 10.0 16.3 10.8 12.0 12.6 21.4 28.6 38.1 50.9 67.9
Inventories, % 36.19 24.89 11.22 11.17 15.6 19.81 19.81 19.81 19.81 19.81
Accounts Payable 11.6 19.3 11.0 13.5 10.4 23.4 31.2 41.7 55.6 74.2
Accounts Payable, % 42.12 29.34 11.37 12.55 12.89 21.65 21.65 21.65 21.65 21.65
Capital Expenditure .0 -2.3 .0 .0 .0 -.8 -1.0 -1.4 -1.8 -2.4
Capital Expenditure, % 0 -3.57 0 0 0 -0.71337 -0.71337 -0.71337 -0.71337 -0.71337
Tax Rate, % -12.56 -12.56 -12.56 -12.56 -12.56 -12.56 -12.56 -12.56 -12.56 -12.56
EBITAT -16.8 -36.9 -37.6 -12.3 -10.5 -38.6 -51.5 -68.8 -91.8 -122.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -16.2 -52.8 -23.8 -9.4 -.5 -29.9 -45.6 -60.9 -81.3 -108.5
WACC, % 22.28 22.28 22 22.28 22.28 22.22 22.22 22.22 22.22 22.22
PV UFCF
SUM PV UFCF -164.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -111
Terminal Value -547
Present Terminal Value -201
Enterprise Value -365
Net Debt -5
Equity Value -360
Diluted Shares Outstanding, MM 6
Equity Value Per Share -65.06

What You Will Get

  • Real Aytu BioPharma Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Aytu BioPharma, Inc. (AYTU).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit Aytu's specific needs.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Aytu BioPharma’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Aytu BioPharma, Inc. (AYTU).
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Aytu BioPharma, Inc. (AYTU).

Key Features

  • Real-Life AYTU Data: Pre-filled with Aytu BioPharma’s historical financials and forward-looking projections.
  • Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures to suit your analysis.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your customized inputs.
  • Scenario Testing: Create multiple forecast scenarios to explore various valuation outcomes.
  • User-Friendly Design: Intuitive, structured layout designed for both professionals and newcomers.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Aytu BioPharma, Inc.'s (AYTU) preloaded data.
  • 2. Adjust Assumptions: Modify essential inputs such as growth projections, WACC, and capital expenditures.
  • 3. Instant Results: The DCF model automatically computes intrinsic value and NPV in real-time.
  • 4. Explore Scenarios: Evaluate various forecasts to investigate different valuation results.
  • 5. Present with Assurance: Deliver expert valuation insights to reinforce your strategic decisions.

Why Choose Aytu BioPharma Calculator?

  • Accuracy: Reliable financial data from Aytu BioPharma ensures precise calculations.
  • Flexibility: Tailored for users to easily modify and experiment with various inputs.
  • Time-Saving: Eliminate the need to create a financial model from the ground up.
  • Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
  • User-Friendly: Intuitive interface designed for users of all financial backgrounds.

Who Should Use This Product?

  • Healthcare Professionals: Understand the latest developments in biopharmaceuticals and their applications.
  • Researchers: Utilize data-driven insights to support studies in drug efficacy and market trends.
  • Investors: Evaluate investment opportunities and analyze valuation metrics for Aytu BioPharma, Inc. (AYTU).
  • Pharmaceutical Analysts: Enhance your analysis with a comprehensive overview of Aytu's product pipeline.
  • Entrepreneurs: Learn from Aytu's strategies in navigating the biopharmaceutical landscape.

What the Template Contains

  • Historical Data: Includes Aytu BioPharma’s past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Aytu BioPharma’s intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Aytu BioPharma’s financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.